
Andrey Sudarikov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2137928/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. Blood, 2021, 137, 1365-1376.	0.6	72
2	Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Molecular Cancer Therapeutics, 2004, 3, 1249-62.	1.9	66
3	Polymorphisms in xenobioticâ€metabolizing genes and the risk of chronic lymphocytic leukemia and nonâ€Hodgkin's lymphoma in adult Russian patients. American Journal of Hematology, 2008, 83, 279-287.	2.0	58
4	Expression level of lipoprotein lipase and dystrophin genes predict survival in B-cell chronic lymphocytic leukemia. Leukemia and Lymphoma, 2007, 48, 912-922.	0.6	30
5	Fluorescence energy transfer-sensitized photobleaching of a fluorescent label as a tool to study donor-acceptor distance distributions and dynamics in protein assemblies: studies of a complex of biotinylated IgM with streptavidin and aggregates of concanavalin A. Journal of Photochemistry and Photobiology B: Biology, 1997, 40, 278-287.	1.7	27
6	Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. Clinical Cancer Research, 2017, 23, 5292-5301.	3.2	27
7	Ribosomal recessive suppressors cause a respiratory deficiency in yeast Saccharomyces cerevisiae. Molecular Genetics and Genomics, 1982, 185, 319-323.	2.4	24
8	Clonal relationship of marginal zone lymphoma and diffuse large B-cell lymphoma in Sjogren's syndrome patients: case series study and review of the literature. Rheumatology International, 2020, 40, 499-506.	1.5	18
9	Differential action of cycloheximide and activation stimuli on transcription of tumor necrosis factor-alpha, IL-1 beta, IL-8, and P53 genes in human monocytes. Journal of Immunology, 1993, 150, 4958-65.	0.4	16
10	National Clinical Guidelines on Diagnosis and Treatment of Ph-Negative Myeloproliferative Neoplasms (Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis) (Edition 2020). Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2021, 14, 262-298.	0.1	15
11	Expansion of CD8+ cells in autoimmune hemolytic anemia. Autoimmunity, 2016, 49, 147-154.	1.2	13
12	Analysis of a single-institution cohort of patients with Felty's syndrome and T-cell large granular lymphocytic leukemia in the setting of rheumatoid arthritis. Rheumatology International, 2021, 41, 147-156.	1.5	13
13	A simple and efficient method for DNA extraction from skin and paraffinâ€embedded tissues applicable to Tâ€cell clonality assays. Experimental Dermatology, 2012, 21, 57-60.	1.4	12
14	VLDL apoprotein secretion and apo-B mRNA level in primary culture of cholesterol-loaded rabbit hepatocytes. FEBS Letters, 1988, 232, 103-106.	1.3	11
15	Inhibitor of BRAFV600E Mutation as a Treatment Option for Hairy Cell Leukemia With Deep Neutropenia and Infectious Complications. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 427-430.	0.2	10
16	Viral Load and Patterns of SARS-CoV-2 Dissemination to the Lungs, Mediastinal Lymph Nodes, and Spleen of Patients with COVID-19 Associated Lymphopenia. Viruses, 2021, 13, 1410.	1.5	10
17	Analysis of T-Cell Receptor-Î ³ Gene Rearrangements Using Oligonucleotide Microchip. Journal of Molecular Diagnostics, 2007, 9, 249-257.	1.2	9
18	Recovery of Donor Hematopoiesis after Graft Failure and Second Hematopoietic Stem Cell Transplantation with Intraosseous Administration of Mesenchymal Stromal Cells. Stem Cells International, 2018, 2018, 1-7.	1.2	9

#	Article	IF	CITATIONS
19	High Incidence of Clonal CD8+ T-cell Proliferation in Non-malignant Conditions May Reduce the Significance of T-cell Clonality Assay for Differential Diagnosis in Oncohematology. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 203-208.	0.2	8
20	Relationship between cytoplasmic and mitochondrial apparatus of protein synthesis in yeast Saccharomyces cerevisiae. Molecular Genetics and Genomics, 1983, 189, 172-174.	2.4	7
21	Tumor necrosis factor Î \pm induction in human monocytes. Cytokine, 1990, 2, 464-469.	1.4	7
22	The Ability of a Recombinant Escherichia coli Strain to Synthesize 2-C-Methyl-D-Erythritol-2,4-Cyclopyrophosphate Correlates with Its Tolerance to In Vitro Induced Oxidative Stress and to the Bactericidal Action of Murine Peritoneal Macrophages. Current Microbiology, 1996, 32, 225-228.	1.0	6
23	Repertoire of Rearranged Immunoglobulin Heavy Chain Genes in Russian Patients With B-Cell Lymphoproliferative Diseases. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e938-e945.	0.2	5
24	7-Ketocholesterol inhibits VLDL secretion by cultured human and rabbit hepatocytes. Biochemical and Biophysical Research Communications, 1988, 153, 1116-1122.	1.0	4
25	Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases. Terapevticheskii Arkhiv, 2018, 90, 23-29.	0.2	4
26	Long-term survival of donor bone marrow multipotent mesenchymal stromal cells implanted into the periosteum of patients with allogeneic graft failure. International Journal of Hematology, 2016, 104, 403-407.	0.7	3
27	International external quality assurance of JAK2 V617F quantification. Annals of Hematology, 2019, 98, 1111-1118.	0.8	3
28	Simultaneous Presentation of Leukemic Non-Nodal Mantle Cell Lymphoma and Gamma-Delta T-Large Granular Lymphocytic Leukemia in a Patient with Rheumatoid Arthritis. Cancer Management and Research, 2020, Volume 12, 9449-9457.	0.9	3
29	Low JAK2 V617F Allele Burden in Ph-Negative Chronic Myeloproliferative Neoplasms Is Associated with Additional CALR or MPL Gene Mutations. Genes, 2021, 12, 559.	1.0	3
30	Genetic Lesions in Russian CLL Patients with the Most Common Stereotyped Antigen Receptors. Blood, 2020, 136, 16-17.	0.6	3
31	Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation. Terapevticheskii Arkhiv, 2018, 90, 14-22.	0.2	3
32	CHEMOTHERAPY ACCORDING TO THE R-mNHL-BFM-90 PROTOCOL IN COMBINATION WITH LENALIDOMIDE AS THE FIRST LINE THERAPY IN PATIENTS WITH MUM1-POSITIVE DIFFUSIVE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA GRADE 3B. Gematologiya I Transfuziologiya, 2019, 64, 150-164.	0.1	3
33	A prospective study of the monitoring of patients with chronic myeloid leukemia upon withdrawal of tyrosine kinase inhibitor therapy. Gematologiya I Transfuziologiya, 2020, 65, 370-385.	0.1	3
34	The non-leukemic T cell large granular lymphocytic leukemia variant with marked splenomegaly and neutropenia in the setting of rheumatoid arthritis - Felty syndrome and hepatosplenic T cell lymphoma mask. American Journal of Blood Research, 2021, 11, 227-237.	0.6	3
35	The difference in p53 antioncogene transcription in human monocytes and lymphocytes. Oncogene, 1992, 7, 549-52.	2.6	3
36	Loss of Heterozygosity in the Tumor DNA of De Novo Diagnosed Patients Is Associated with Poor Outcome for B-ALL but Not for T-ALL. Genes, 2022, 13, 398.	1.0	3

#	Article	IF	CITATIONS
37	Structure and prognostic signifi cance of 13q14 deletion in chronic lymphocytic leukemia. Gematologiya I Transfuziologiya, 2022, 67, 75-89.	0.1	3
38	STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma. Current Oncology, 2022, 29, 3449-3459.	0.9	3
39	Probe for rabbit apolipoprotein B gene. Nucleic Acids Research, 1988, 16, 8187-8187.	6.5	2
40	<scp>BCR</scp> â€ <scp>ABL</scp> exon 7 deletion and novel point mutation in patient with chronic myelogenous leukemia and <scp>TKI</scp> resistance. Clinical Case Reports (discontinued), 2018, 6, 2057-2060.	0.2	2
41	The Role of Genetic Polymorphisms of <i>TPMT</i> and <i>NUDT15</i> Genes in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia in Russia. Blood, 2020, 136, 21-22.	0.6	2
42	MYD88 L265P Mutation Is a Possible Unfavorable Prognostic Factor in Patients with Diffuse B-Cell Lymphoma. Blood, 2015, 126, 5051-5051.	0.6	2
43	Diagnostics and treatment challenges of Ph-like acute lymphoblastic leukemia: a description of 3 clinical cases. Terapevticheskii Arkhiv, 2018, 90, 110-117.	0.2	2
44	First experience of using Brentuximab vedotin and modified program NHL-BFM-90 in the front-line treatment of patient with anaplastic large-cell lymphoma: a case report and a review of literature. Terapevticheskii Arkhiv, 2018, 90, 77-81.	0.2	2
45	Treatment of Chronic Myeloid Leukemia According to Current Guidelines: The Results of the Pilot Prospective Study "Early Induction Therapy and Monitoring― Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2019, 12, 94-101.	0.1	2
46	Next-generation sequencing-based molecular genetic profiling in adults with acute myeloid leukaemia. Gematologiya I Transfuziologiya, 2020, 65, 444-459.	0.1	2
47	Immunologically related proteins in cytoplasmic and mitochondrial ribosomes of yeast Saccharomyces cerevisiae. Molecular Genetics and Genomics, 1986, 203, 316-319.	2.4	1
48	Genetic Polymorphisms of TPMT and NUDT15 Genes and Thiopurine Treatment-Related Toxicity in Adult Patients with Acute Lymphoblastic Leukemia in Russia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S191-S192.	0.2	1
49	Pitfalls in mononucleotide microsatellite repeats instability assessing (MSI) in the patients with B-cell lymphomas. Klinichescheskaya Laboratornaya Diagnostika, 2021, 66, 181-186.	0.2	1
50	Microsatellite instability (MSI, EMAST) in the pathogenesis of follicular lymphoma. Oncogematologiya, 2021, 16, 56-69.	0.1	1
51	Significance of TPMT and NUDT15 variants in 6-mercaptopurine metabolism in acute lymphoblastic leukaemia/lymphoma patients. Gematologiya I Transfuziologiya, 2021, 66, 253-262.	0.1	1
52	The Frequency of Calr and MPL Gene Mutations in Jak2 V617F - Positive Chronic Myeloproliferative Neoplasms in Russia. Blood, 2019, 134, 5400-5400.	0.6	1
53	Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites. Blood, 2016, 128, 4376-4376.	0.6	1
54	Inhibition of potassium currents as a pharmacologic target for investigation in chronic lymphocytic leukemia. Drug News and Perspectives, 2010, 23, 625.	1.9	1

#	Article	IF	CITATIONS
55	QUANTITATIVE RHOA Gly17Val ALLELE-SPECIFIC POLYMERASE CHAIN REACTION AND T-CELL CLONALITY ANALYSIS IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA. Oncogematologiya, 2018, 12, 41-49.	0.1	1
56	PB1874 STEREOTYPE ANTIGEN RECEPTORS IN B ELL LYMPHOPROLIFERATIVE DISEASES. HemaSphere, 2019, 3 854.	1.2	1
57	First experience of allogeneic haematopoietic stem cell transplantation in patients with mantle cell lymphoma with a mutation in the <i>TP53</i> gene. Gematologiya I Transfuziologiya, 2020, 65, 483-500.	0.1	1
58	ЕNew Combination of Prognostic Markers in Follicular Lymphoma That Influences the Choice of Therapy. Blood, 2021, 138, 4520-4520.	0.6	1
59	How to Avoid False-Negative and False-Positive COVID-19 PCR Testing. International Journal of Translational Medicine, 2022, 2, 204-209.	0.1	1
60	Molecular and genetic verification of von Willebrand disease type 2N. Gematologiya I Transfuziologiya, 2022, 67, 172-180.	0.1	1
61	Cycloheximide dependence of TNF-α gene transcription in activated human monocytes. Cytokine, 1991, 3, 456.	1.4	0
62	Synthesis of tumor necrosis factor ? (TNF-?) by human monocytes in vitro. Bulletin of Experimental Biology and Medicine, 1991, 112, 1302-1305.	0.3	0
63	Differences in "antioncogene―p53 expression in human monocytes and lymphocytes in vitro. Bulletin of Experimental Biology and Medicine, 1992, 113, 856-859.	0.3	0
64	Transfection of the Newcastle disease virus hemagglutinin-neuraminidase gene into murine myeloma cells for induction of host-versus-tumor immune response. Doklady Biochemistry and Biophysics, 2001, 378, 217-220.	0.3	0
65	5.31 Factors Associated with Complete Response and Treatment Failure in Primary CLL Patients Treated with Fludarabine, Cyclophosphamide and Rituximab: First Interim Analysis of MLSG08_1 Trial. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S264.	0.2	0
66	BRAF and MAP2K1 Genes Mutation in Splenic Marginal Zone Lymphoma and Hairy Cell Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S99-S100.	0.2	0
67	IgVH Genes Somatic Mutations in Splenic Marginal Zone Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S122.	0.2	0
68	High Incidence of Clonal CD8+ T-Cell Proliferation in Non-Malignant Conditions May Hamper the Value of T-Cell Clonality Assay for Differential Diagnosis in Oncohematology. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S299-S300.	0.2	0
69	Differences in IGHV Gene Usage and Stereotypic Receptors in CLL and SMZL. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S299.	0.2	0
70	Stereotype Antigen Receptors in B-Cell Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S284.	0.2	0
71	ALL-332: Loss of Heterozygosity in the Short Tandem Repeat (STR) Loci Found in Tum or DNA of De Novo-Diagnosed ALL Patients as a Factor Predicting Poor Outcome. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S171.	0.2	0
72	ALL-351: NRAS, KRAS, JAK2, CRLF2, TP53 Mutations in Adult ALL patients. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S171-S172.	0.2	0

#	Article	IF	CITATIONS
73	CLL-263: Genetic Lesions Associated with CLL#1 Subset Patients in Russia. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S226.	0.2	0
74	CLL-264: CLL Patients with Identical IGHV Genes. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S226.	0.2	0
75	CML-143: BCR-ABL1 Translocation Combined with JAK2 or CALR Mutations in Russian CML Patients Undergoing TKI Therapy: Transcript Level and Mutation Allele Burden. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S235-S236.	0.2	0
76	CML-266: Second Generation Tyrosine Kinase Inhibitors in First Line Can Reduce the Time to Treatment-Free Remission in Chronic Myeloid Leukemia Patients. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S239.	0.2	0
77	ABCL-349: Genetic Instability of Microsatellite Loci in Primary Mediastinal B-cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S274-S275.	0.2	0
78	IBCL-327: Genetic Instability (MSI, EMAST) in Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S283.	0.2	0
79	IBCL-338: The Incidence of Composite Lymphomas: One Center Experience (Russia). Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S283-S284.	0.2	0
80	Composite Epstein-Barr virus-positive mucosa-associated lymphoid tissue lymphoma and Epstein-Barr virus-negative diffuse large B-cell lymphoma in the parotid salivary gland of a patient with Sjögren's syndrome and rheumatoid arthritis: a case report. Journal of Medical Case Reports, 2020, 14, 12.	0.4	0
81	Thrombosis in patients with myeloproliferative neoplasms. Case report. Terapevticheskii Arkhiv, 2021, 93, 800-804.	0.2	0
82	Li–Fraumeni syndrome in adult patients with acute lymphoblastic leukemia. Terapevticheskii Arkhiv, 2021, 93, 763-769.	0.2	0
83	Development of program therapy for patients with acute myeloid leukemia under the age of 60 years, based on the principles of differentiated effects. Terapevticheskii Arkhiv, 2021, 93, 753-762.	0.2	0
84	Multiple primary tumor of hematopoietic tissue: myeloid sarcoma in combination with mantle cell lymphoma. Case report. Terapevticheskii Arkhiv, 2021, 93, 793-799.	0.2	0
85	Poster: AML-260: Influence of Chimerism in T-Regulatory Cells on Relapse Rate in Acute Leukemia Patients after Allo-HSCT. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S214.	0.2	0
86	Long-Term Monitoring of Patients with Hematological Malignancies and Hepatitis B and Hepatitis C Virus Infections. Blood, 2008, 112, 3976-3976.	0.6	0
87	Hepatitis B and Hepatitis C Co-Infection in Patients with Hematological Malignancies. Blood, 2011, 118, 2090-2090.	0.6	0
88	The Repertoire of Heavy Chain Immunoglobulin Genes in B-Cell Chronic Lymphocytic Leukemia in Russia and Belarus. Blood, 2012, 120, 4579-4579.	0.6	0
89	Low Frequency Of IGHV4-39/IGHD6-13/IGHJ5 Rearrangement With Stereotyped HCDR3 (subset #8) In Russian and Ukrainian Chronic Lymphocytic Leukemia Patients. Blood, 2013, 122, 5276-5276.	0.6	0
90	Photokinetic Detection of Fluorescence Energy Transfer in Protein Assemblies Using Photobleaching of Energy Acceptor. , 1997, , 21-22.		0

#	Article	IF	CITATIONS
91	Detection of B-Cell Clonality in Bone Marrow Is Independent Predictor of Outcome in De Novo Diffuse Large B-Cell Lymphoma Patients Treated with High-Dose Chemotherapy. Blood, 2014, 124, 2967-2967.	0.6	0
92	Detection of T-Cell Clonality in Bone Marrow in Peripheral T-Cell Lymphoma, Not Otherwise Specified. Blood, 2015, 126, 5020-5020.	0.6	0
93	Multiple Clonal TCR Gene Rearrangements Are Typical in Peripheral T-Cell Lymphoma Not Otherwise Specified. Blood, 2015, 126, 5036-5036.	0.6	0
94	CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous: Antigen Receptor Stereotypy Makes the Difference. Blood, 2015, 126, 5263-5263.	0.6	0
95	Pathomorphological Diagnosis of Splenic Diffuse Red Pulp Small B-Cell Lymphoma. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2016, 9, 287-295.	0.1	Ο
96	Clonal CD57+ Cells in T-Cell Large Granular Lymphocytic Leukemia. Blood, 2016, 128, 4904-4904.	0.6	0
97	V(D)J Recombination Excision Circles of B- and T-cells as Prognostic Marker in B-Cell Chronic Lymphocytic Leukemia. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2017, 10, 131-140.	0.1	0
98	Hodgkin's Disease and Paraproteinaemia. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S324-S325.	0.2	0
99	lgvh Somatic Mutation Profile in Splenic Lymphomas: Opportunities for Differential Diagnosis. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S389.	0.2	0
100	Are the Minimal Residual Disease Status and IKZF1 Mutations Play Prognostic Role in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Treated by RALL Protocols?. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S268.	0.2	0
101	Repertoire of IgVH Genes in Splenic Marginal Zone Lymphoma Complicated with Autoimmune Hemolytic Anemia. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S391.	0.2	0
102	Coinheritance of HbD-Punjab/β+-thalassemia (IVSI+5 G-C) in patient with Gilbert's syndrome. Terapevticheskii Arkhiv, 2018, 90, 105-109.	0.2	0
103	Loss of Heterozygosity and Possible Loss of Allele Amplification in Homozygous Short Tandem Repeats Loci in Two ALL Patients with Central Nervous System and Bone Marrow Relapses. Blood, 2018, 132, 5135-5135.	0.6	0
104	Loss of Heterozygosity in the Short Tandem Repeat (STR) Loci Found in Tumor DNA of De Novo Diagnosed ALL Patients As a Factor Predicting Poor Outcome. Blood, 2019, 134, 5204-5204.	0.6	0
105	HLA Alleles Repertoire in Russian CLL Patients. Blood, 2019, 134, 5462-5462.	0.6	0
106	R-m-NHL-BFM-90/R-EPOCH Protocol in the Treatment of Patients with Primary Mediastinal Lymphoma: First Results. Blood, 2019, 134, 5334-5334.	0.6	0
107	HLA allele repertoire in Russian chronic lymphocytic leukemia patients with an unfavorable prognosis. Gematologiya I Transfuziologiya, 2020, 65, 312-320.	0.1	0
108	Frequency of coexistence and kinetics of the BCR-ABL1 transcript level and allele burden of JAK2V617F and CALR Type 1, 2 gene mutations in patients with chronic myeloid leukemia. Gematologiya I Transfuziologiya, 2020, 65, 253-280.	0.1	0

#	Article	IF	CITATIONS
109	Clinical Exome Sequencing in B-Cell Ph-Negative ALL Patient Demonstrates Clonal Changes at Different Stages of the Disease. Blood, 2020, 136, 9-10.	0.6	0
110	RT-PCR isotyping of murine Ig-secreting cell lines. BioTechniques, 1995, 18, 628-31.	0.8	0
111	Analysis of microsatellite aberrations and loss of heterozygosity in follicular lymphoma, diffuse large B-cell lymphoma, and high-grade B-cell lymphoma patients. Oncogematologiya, 2022, 17, 60-74.	0.1	0
112	Evaluation of Heterozygosity Loss in STR-Loci of Tumor DNA in Multiple Myeloma Patients with Plasmacytoma Based on the Molecular Analysis of Complex Archival Tumor Samples. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2022, 15, 156-166.	0.1	0